Skip to content

Metabolism and disposition of N,N‐dimethyltryptamine and harmala alkaloids after oral administration of ayahuasca

Jordi Riba, Ethan H. Mcilhenny, Marta Valle, José Carlos Bouso, Steven A. Barker

Drug Testing and Analysis April 19, 2012 DOI: 10.1002/dta.1344 via OpenAlex

Summary

AI-generated from the abstract

Ayahuasca, an Amazonian tea containing β-carboline alkaloids (harmine, harmaline, tetrahydroharmine) and the psychedelic DMT, is used worldwide, but its metabolism in humans had not been systematically studied. In 10 healthy men given freeze-dried ayahuasca (1.0 mg DMT/kg), less than 1% of DMT was excreted unchanged; about 50% was recovered as indole-3-acetic acid, 10% as DMT-N-oxide, and total DMT plus metabolites reached 68%. Harmala alkaloids were excreted as O-demethylated and conjugated metabolites, but recoveries varied from 9% to 65%. The findings indicate alternative metabolic routes for DMT beyond monoamine-oxidase and that O-demethylation plus conjugation is important but not the only pathway for harmala alkaloids.

Study at a glance

Characteristics Observational pharmacokinetic study Peer reviewed
Sample size 10
Population Healthy male volunteers
Dose 1.0 mg DMT/kg body weight
Topics Ayahuasca
Keywords Harmine Harmaline Chemistry Alkaloid
Citations 91
Key finding In humans, less than 1% of oral DMT is excreted unchanged, with alternative metabolic routes beyond monoamine-oxidase accounting for about 68% recovery, while harmala alkaloid recoveries vary widely (9–65%) via O-demethylation and conjugation.

Abstract

Ayahuasca is an Amazonian psychotropic plant tea obtained from Banisteriopsis caapi , which contains β ‐carboline alkaloids, chiefly harmine, harmaline and tetrahydroharmine. The tea usually incorporates the leaves of Psychotria viridis or Diplopterys cabrerana , which are rich in N , N ‐dimethyltryptamine (DMT), a psychedelic 5‐HT 2A/1A/2C agonist. The β ‐carbolines reversibly inhibit monoamine‐oxidase (MAO), effectively preventing oxidative deamination of the orally labile DMT and allowing its absorption and access to the central nervous system. Despite increased use of the tea worldwide, the metabolism and excretion of DMT and the β ‐carbolines has not been studied systematically in humans following ingestion of ayahuasca. In the present work, we used an analytical method involving high performance liquid chromatography (HPLC)/electrospray ionization (ESI)/selected reaction monitoring (SRM)/tandem mass spectrometry(MS/MS) to characterize the metabolism and disposition of ayahuasca alkaloids in humans. Twenty‐four‐hour urine samples were obtained from 10 healthy male volunteers following administration of an oral dose of encapsulated freeze‐dried ayahuasca (1.0 mg DMT/kg body weight). Results showed that less than 1% of the administered DMT dose was excreted unchanged. Around 50% was recovered as indole‐3‐acetic acid but also as DMT‐ N ‐oxide (10%) and other MAO‐independent compounds. Recovery of DMT plus metabolites reached 68%. Harmol, harmalol, and tetrahydroharmol conjugates were abundant in urine. However, recoveries of each harmala alkaloid plus its O ‐demethylated metabolite varied greatly between 9 and 65%. The present results show the existence in humans of alternative metabolic routes for DMT other than biotransformation by MAO. Also that O ‐demethylation plus conjugation is an important but probably not the only metabolic route for the harmala alkaloids in humans. Copyright © 2012 John Wiley & Sons, Ltd.

Explore topics

Comments

No comments yet.

Log in to comment